Visão selecionada em Inglês
Descritor em português: | Zalcitabina | ||||||
Descritor em inglês: | Zalcitabine | ||||||
Descritor em espanhol: |
Zalcitabina
| ||||||
Descritor em francês: | Zalcitabine | ||||||
Termo(s) alternativo(s): |
2',3' Dideoxycytidine 2',3'-Dideoxycytidine Dideoxycytidine HIVID Roche Hivid NSC 606170 NSC-606170 NSC606170 ddC (Antiviral) |
||||||
Código(s) hierárquico(s): |
D03.383.742.680.245.500.950 D13.570.230.329.950 D13.570.230.500.925 D13.570.685.245.500.950 |
||||||
Identificador Único RDF: | https://id.nlm.nih.gov/mesh/D016047 | ||||||
Nota de escopo: | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. |
||||||
Qualificadores permitidos: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Ação Farmacológica: |
Antimetabólitos Inibidores da Transcriptase Reversa Fármacos Anti-HIV |
||||||
Número de registro: | 6L3XT8CB3I | ||||||
Nome CAS Tipo 1: | Cytidine, 2',3'-dideoxy- | ||||||
Indexação Anterior: |
Deoxycytidine/analogs & derivatives (1986-1989) Dideoxynucleosides (1989) |
||||||
Nota MeSH pública: | 94; was DIDEOXYCYTIDINE 1990-93 |
||||||
Nota Online: | use ZALCITABINE to search DIDEOXYCYTIDINE 1990-93 |
||||||
Nota histórica: | 94; was DIDEOXYCYTIDINE 1990-93 |
||||||
Identificador DeCS: | 31821 | ||||||
ID do descritor: | D016047 | ||||||
Documentos indexados na Biblioteca Virtual em Saúde (BVS): | Clique aqui para acessar os documentos da BVS | ||||||
Data de estabelecimento: | 01/01/1990 | ||||||
Data de entrada: | 14/07/1989 | ||||||
Data de revisão: | 24/05/2017 |
-
-
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
Zalcitabine
- Conceito preferido
NSC-606170
- Mais específico
Hivid
- Mais específico
Identificador do conceito |
M0024532 |
Nota de escopo | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. |
Termo preferido | Zalcitabine |
Termo(s) alternativo(s) |
2',3' Dideoxycytidine 2',3'-Dideoxycytidine Dideoxycytidine ddC (Antiviral) |
Identificador do conceito |
M0332662 |
Termo preferido | NSC-606170 |
Termo(s) alternativo(s) |
NSC 606170 NSC606170 |
Identificador do conceito |
M0024533 |
Termo preferido | Hivid |
Termo(s) alternativo(s) |
HIVID Roche |
Queremos a sua opinião sobre o novo sitio web do DeCS/MeSH
Convidamos-lhe a responder a uma pesquisa que não levará mais que 3 minutos
Ir para pesquisa